Literature DB >> 9423170

Is Cmax/AUC useful for bioequivalence testing?

A Rostami-Hodjegan, G T Tucker.   

Abstract

Mesh：

Year:  1997        PMID： 9423170     DOI： 10.1021/js970153t

Source DB:  PubMed          Journal:  J Pharm Sci        ISSN： 0022-3549            Impact factor:   3.534


× No keyword cloud information.
  5 in total

1.  The role of metabolites in bioequivalency assessment. III. Highly variable drugs with linear kinetics and first-pass effect.

Authors:  A J Jackson
Journal:  Pharm Res       Date:  2000-11       Impact factor: 4.200

2.  Novel direct curve comparison metrics for bioequivalence.

Authors:  J E Polli; A M McLean
Journal:  Pharm Res       Date:  2001-06       Impact factor: 4.200

Review 3.  Evaluation of bioequivalence for highly variable drugs with scaled average bioequivalence.

Authors:  Laszlo Tothfalusi; Laszlo Endrenyi; Alfredo Garcia Arieta
Journal:  Clin Pharmacokinet       Date:  2009       Impact factor: 6.447

4.  The Two Main Goals of Bioequivalence Studies.

Authors:  Laszlo Endrenyi; Henning H Blume; Laszlo Tothfalusi
Journal:  AAPS J       Date:  2017-02-02       Impact factor: 4.009

5.  Bioequivalence testing by statistical shape analysis.

Authors:  Luis Marcelo Pereira
Journal:  J Pharmacokinet Pharmacodyn       Date:  2007-06-07       Impact factor: 2.410
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.